Yarrow Bioscience Prices $150M Underwritten Offering at $26.00 Per Share
YARW sits 85% above its 52-week low of $14.63 on elevated volume (26× avg).
Summary
Yarrow Bioscience priced a 5.77 million share underwritten offering at $26.00 per share, raising approximately $140.7 million in net proceeds to fund operations into 2030.
Key Events · Financing and Capital Events · YARW
-
Underwritten Offering Priced at $26.00
5,769,231 shares of common stock priced at $26.00 per share for gross proceeds of $150,000,006. Underwriters have a 30-day option to purchase up to 865,384 additional shares.
-
Net Proceeds of $140.7 Million
After underwriting discounts of $1.56 per share ($9.0 million total) and estimated expenses of $350,000, net proceeds are approximately $140.7 million, or $161.8 million if the option is exercised in full.
-
Cash Position of $108.8 Million
Preliminary cash and cash equivalents estimate of $108.8 million as of August 31, 2026, up from $18.7 million as of June 30, 2026, reflecting proceeds from the VYNE merger and other financing activities.
-
Runway Extended into 2030
Management expects net proceeds combined with existing cash to fund operations into 2030, including completion of the Phase 2b Graves' disease trial and preparatory work for the next planned thyroid eye disease study.
Analysis · YARW · Life Sciences
Yarrow Bioscience finalized terms of its underwritten public offering, selling 5.77 million shares at $26.00 each for gross proceeds of $150 million. Net proceeds of approximately $140.7 million will fund operations into 2030, including completion of the Phase 2b Graves' disease trial. The offering price represents a 10.7% discount to the last reported sale price of $29.11 on September 9, 2026, and a 3.7% discount to today's price of $27.01. The company's cash position of $108.8 million as of August 31, 2026, combined with these proceeds, provides substantial runway for a clinical-stage biotech with a market cap of approximately $72 million.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.2% of the 1943 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, YARW was trading at $27.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $72.1M. The 52-week trading range was $14.63 to $46.95. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.